Norvasc

General

Amlodipine is generally well-tolerated at doses up to 10 mg per day. Most adverse responses revealed were of light or average intensity and were dose-related. Frustration and hydropsy are the most typical adverse responses.


Amlodipine has been used securely in sufferers with serious obstructive lung condition, well-compensated congestive center failing, center, side-line general condition, diabetic issues, and irregular fat information.

Other

Other adverse responses have involved hydropsy (up to 14.6%), eliminating (up to 4.5%), exhaustion (4.5%), and back problems (up to 2%). During research in sufferers with recorded center, the most typical complication was side-line hydropsy. Asthenia, hot eliminates, malaise, discomfort, and suffering have been revealed in less than 1% but higher than 0.1% of sufferers. Cold and sticky epidermis and parosmia have been revealed in less than 0.1% of sufferers.

Cardiovascular

Cardiovascular adverse responses have involved palpitations (up to 4.5%). Arrhythmia (including ventricular tachycardia and atrial fibrillation), bradycardia, discomfort in stomach area, hypotension, side-line ischemia, posture hypotension, tachycardia, and vasculitis have been revealed in less than 1% but higher than 0.1% of sufferers. Heart failing, extrasystoles, and beat irregularity have been revealed in less than 0.1% of sufferers. Angina and myocardial infarction have sometimes been reported; however, these responses could not be recognized from coexisting condition declares or medicines. Difficult angina and serious myocardial infarction can create after beginning or increasing the amount of amlodipine, especially in sufferers with serious obstructive center.

Nervous system

Nervous program adverse responses have involved pain (7.3%), wooziness (up to 3.4%), and somnolence (up to 1.6%). Hypoesthesia, paresthesia, side-line neuropathy, posture wooziness, syncope, ears ringing, tremor, and vertigo have been revealed in less than 1% but higher than 0.1% of sufferers. Ataxia and headaches have been revealed in less than 0.1% of sufferers. Myoclonus has been revealed.

Gastrointestinal

Gastrointestinal adverse responses have involved nausea or throwing up (2.9%), dysphagia (up to 2%), and stomach discomfort (1.6%). Anorexia, bowel problems, diarrhoea, dry mouth, dyspepsia, unwanted gas, gingival hyperplasia, pancreatitis, and throwing up have been revealed in less than 1% but higher than 0.1% of sufferers. Gastritis, improved hunger, reduce chairs, and flavor perversion have been revealed in less than 0.1% of sufferers. At least one situation of amlodipine-associated dysgeusia has been revealed and verified upon rechallenge.

Hematologic

Hematologic adverse responses have involved leukopenia, purpura, and thrombocytopenia in less than 1% but higher than 0.1% of sufferers.

A example reviews a 34-year-old woman with a history of serious kidney failing additional to glomerulonephritis, who was started on amlodipine for out of control high blood pressure. Three times later the affected person designed serious thrombocytopenia. After stopping of the medication, the platelet depend came back to normal.

Hepatic

Hepatic adverse responses have involved jaundice and hepatic compound heights (mostly constant with cholestasis or hepatitis) during postmarketing encounter. In some circumstances, these cases were serious enough to require hospital stay.

Metabolic

Metabolic adverse responses have involved hyperglycemia, hunger, bodyweight reduce, and excess bodyweight in less than 1% but higher than 0.1% of sufferers. New-onset diabetic issues has been revealed. A single situation of serious porphyria exacerbation has been associated with the use of amlodipine, and verified upon rechallenge in the same individual. Calcium mineral route blockers have been recommended as possibly risky in sufferers with this condition.

Musculoskeletal

Musculoskeletal adverse responses have involved myalgia (up to 2%). Arthralgia, arthrosis, and muscular pain have been revealed in less than 1% but higher than 0.1% of sufferers. Hypertonia, muscular weak point, and twitching have been revealed in less than 0.1% of sufferers.

Psychiatric

Psychiatric adverse responses have involved male impotence (up to 2%). Abnormal goals, anxiety, depersonalization, depressive disorders, women impotence, sleeplessness, and anxiety have been revealed in less than 1% but higher than 0.1% of sufferers. Frustration, amnesia, and apathy have been revealed in less than 0.1% of sufferers.

Dermatologic

A 62-year-old man with high blood pressure and skin psoriasis designed erythema multiforme within three times after beginning amlodipine. The allergy settled upon alternative with nifedipine.

Dermatologic adverse responses have involved allergy and erythematous allergy in up to 2% of sufferers. Angioedema, erythema multiforme, improved perspiration, maculopapular allergy, and pruritus have been revealed in less than 1% but higher than 0.1% of sufferers. Hair loss, dermatitis, epidermis color, dry epidermis, and urticaria have been revealed in less than 0.1% of sufferers. Amlodipine-associated lichen planus and telangiectasia have been hardly ever revealed. At least one situation of amlodipine-associated bullous pemphigoid (with erythema multiforme-like scientific features) has been revealed.

Ocular

Ocular adverse responses have involved irregular perspective, conjunctivitis, diplopia, and eye discomfort in less than 1% but higher than 0.1% of sufferers. Abnormal graphic housing and xerophthalmia have been revealed in less than 0.1% of sufferers.

Respiratory

Respiratory adverse responses have involved epistaxis (up to 2%) and dyspnea (less than 1% but higher than 0.1%). Hacking and coughing and rhinitis have been revealed in less than 0.1% of sufferers. Pulmonary hydropsy was revealed during a research of sufferers with NYHA Class III or IV center failing without scientific symptoms or purpose proof of actual ischemic condition.

Genitourinary

Genitourinary adverse responses have involved micturition problem, micturition regularity, and nocturia in less than 1% but higher than 0.1% of sufferers. Dysuria and polyuria have been revealed in less than 0.1% of sufferers.

Hypersensitivity

Hypersensitivity adverse responses have involved sensitivity (less than 1% but higher than 0.1%).

Endocrine

In one situation, a individual's man boobs settled upon alternative of amlodipine with an irrelevant antihypertensive broker.

Endocrine adverse responses have involved man boobs during postmarketing encounter.

Renal

Renal adverse responses have been revealed hardly ever. At least one situation of interstitial nephritis has been associated with amlodipine treatment.